A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Introduction: Unlike for glucose, uptake of the brain's main alternative fuel, ketones, remains normal in mild cognitive impairment (MCI). Ketogenic medium chain triglycerides (kMCTs) could improve cognition in MCI by providing the brain with more fuel. Methods: Fifty‐two subjects with MCI were blindly randomized to 30 g/day of kMCT or matching placebo. Brain ketone and glucose metabolism (quantified by positron emission tomography; primary outcome) and cognitive performance (secondary outcome) were assessed at baseline and 6 months later. Results: Brain ketone metabolism increased by 230% for subjects on the kMCT (P < .001) whereas brain glucose uptake remained unchanged. Measures of episodic memory, language, executive function, and processing speed improved on the kMCT versus baseline. Increased brain ketone uptake was positively related to several cognitive measures. Seventy‐five percent of participants completed the intervention. Discussion: A dose of 30 g/day of kMCT taken for 6 months bypasses a significant part of the brain glucose deficit and improves several cognitive outcomes in MCI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025 · cited 2×
“*Geriatric depression screening scale [26].”
BackgroundMedium-chain triglycerides: an update
Bach, A., & Babayan, V. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.5.950 · Cited by 1,151
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
Marten, B., Pfeuffer, M., & Schrezenmeir, J. (2006) · International Dairy Journal · doi:10.1016/j.idairyj.2006.06.015 · Cited by 456
Ota, M., Matsuo, J., Ishida, I., Takano, H., Yokoi, Y., Hori, H., Yoshida, S., Ashida, K., Nakamura, K., Takahashi, T., et al. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.10.048 · Cited by 276 · cited 2×
“The modest but significant cognitive benefit observed in the present MCI study is also consistent with three previous assessments of kMCT in AD, one of which was acute and uncontrolled [55], and the two other were placebo-controlled and of 2 to 3 months duration [18,21].”
MethodResultCroteau, E., Castellano, C. A., Fortier, M., Bocti, C., Fulop, T., Paquet, N., & Cunnane, S. C. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.07.004 · Cited by 258
Self-citationCunnane, S. C., Courchesne‐Loyer, A., St‐Pierre, V., Vandenberghe, C., Pierotti, T., Fortier, M., Croteau, E., & Castellano, C. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12999 · Cited by 250
Self-citationCourchesne-Loyer, A., Croteau, E., Castellano, C.-A., St-Pierre, V., Hennebelle, M., & Cunnane, S. C. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16669366 · Cited by 169
Self-citationKetogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer’s Disease
Croteau, E., Castellano, C.-A., Richard, M. A., Fortier, M., Nugent, S., Lepage, M., Duchesne, S., Whittingstall, K., Turcotte, É. E., Bocti, C., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180202 · Cited by 135
Self-citation
Cited by
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003
Self-citationEffects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases
Jensen, N. J., Wodschow, H. Z., Nilsson, M., & Rungby, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228767 · Cited by 446
Cognitive symptoms of Alzheimer’s disease: clinical management and prevention
Joe, E., & Ringman, J. M. (2019) · BMJ · doi:10.1136/bmj.l6217 · Cited by 321
Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives
Beard, E., Lengacher, S., Dias, S., Magistretti, P. J., & Finsterwald, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.825816 · Cited by 302
Role of diet and its effects on the gut microbiome in the pathophysiology of mental disorders
Horn, J., Mayer, D. E., Chen, S., & Mayer, E. A. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01922-0 · Cited by 193
“Several clinical pilot studies additionally confirmed the positive effect of a medium chain triglyceride (MCT) diet on ADAS-cog outcomes in adults with mildto-moderate AD, with observations of an acute improvement on the ADAS-cog [100], a long-term significant improvement in immediate and delayed logical memory and di…”
Background
Metadata
- Authors
- Fortier, M., Castellano, C., Croteau, E., Langlois, F., Bocti, C., St‐Pierre, V., Vandenberghe, C., Bernier, M., Roy, M., Descoteaux, M., Whittingstall, K., Lepage, M., Turcotte, É. E., Fulop, T., & Cunnane, S. C.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2019-04-23
- Volume
- 15
- Issue
- 5
- Pages
- 625-634
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2941655008
- Cited by
- 216
- References
- 11
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.